PDE5A and Alzheimer disease: Treatment of mouse (APP/PS1 animals) and rat (Aβ injection in the hippocampus) models of AD with these compounds decreased expression of APP, Aβ, and PDE5 and significantly attenuated AD-related cognitive deficits [209,210].